253 related articles for article (PubMed ID: 37332996)
1. A review of studies on gut microbiota and levodopa metabolism.
Zhong Z; Ye M; Yan F
Front Neurol; 2023; 14():1046910. PubMed ID: 37332996
[TBL] [Abstract][Full Text] [Related]
2. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Cui C; Han Y; Li H; Yu H; Zhang B; Li G
Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between Gut Bacteria and Levodopa Metabolism.
Xu K; Sheng S; Zhang F
Curr Neuropharmacol; 2023; 21(7):1536-1547. PubMed ID: 36278467
[TBL] [Abstract][Full Text] [Related]
4. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
van Kessel SP; Bullock A; van Dijk G; El Aidy S
mSystems; 2022 Feb; 7(1):e0119121. PubMed ID: 35076270
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori infection and Parkinson's Disease: etiology, pathogenesis and levodopa bioavailability.
Wei BR; Zhao YJ; Cheng YF; Huang C; Zhang F
Immun Ageing; 2024 Jan; 21(1):1. PubMed ID: 38166953
[TBL] [Abstract][Full Text] [Related]
7. Gut bacterial deamination of residual levodopa medication for Parkinson's disease.
van Kessel SP; de Jong HR; Winkel SL; van Leeuwen SS; Nelemans SA; Permentier H; Keshavarzian A; El Aidy S
BMC Biol; 2020 Oct; 18(1):137. PubMed ID: 33076930
[TBL] [Abstract][Full Text] [Related]
8. New hope for Parkinson's disease treatment: Targeting gut microbiota.
Fan HX; Sheng S; Zhang F
CNS Neurosci Ther; 2022 Nov; 28(11):1675-1688. PubMed ID: 35822696
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori eradication for Parkinson's disease.
Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
[TBL] [Abstract][Full Text] [Related]
10. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.
van Kessel SP; El Aidy S
Front Neurol; 2019; 10():1087. PubMed ID: 31681153
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
Leta V; Klingelhoefer L; Longardner K; Campagnolo M; Levent HÇ; Aureli F; Metta V; Bhidayasiri R; Chung-Faye G; Falup-Pecurariu C; Stocchi F; Jenner P; Warnecke T; Ray Chaudhuri K;
Eur J Neurol; 2023 May; 30(5):1465-1480. PubMed ID: 36757008
[TBL] [Abstract][Full Text] [Related]
12. Effects of levodopa on gut bacterial antibiotic resistance in Parkinson's disease rat.
Sheng S; Li X; Zhao S; Zheng C; Zhang F
Front Aging Neurosci; 2023; 15():1122712. PubMed ID: 36824263
[TBL] [Abstract][Full Text] [Related]
13. The gut microbiome in Parkinson's disease: A culprit or a bystander?
Keshavarzian A; Engen P; Bonvegna S; Cilia R
Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
[TBL] [Abstract][Full Text] [Related]
14. Altered gut microbiota in Parkinson's disease patients with motor complications.
Takahashi K; Nishiwaki H; Ito M; Iwaoka K; Takahashi K; Suzuki Y; Taguchi K; Yamahara K; Tsuboi Y; Kashihara K; Hirayama M; Ohno K; Maeda T
Parkinsonism Relat Disord; 2022 Feb; 95():11-17. PubMed ID: 34954497
[TBL] [Abstract][Full Text] [Related]
15. New insights into pathogenesis of l-DOPA-induced dyskinesia.
Zheng C; Zhang F
Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
[TBL] [Abstract][Full Text] [Related]
16. The Role of Gut Microbiota in the Progression of Parkinson's Disease and the Mechanism of Intervention by Traditional Chinese Medicine.
Huan P; Wang L; He Z; He J
Neuropsychiatr Dis Treat; 2022; 18():1507-1520. PubMed ID: 35923300
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
18. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
Wang Y; Tong Q; Ma SR; Zhao ZX; Pan LB; Cong L; Han P; Peng R; Yu H; Lin Y; Gao TL; Shou JW; Li XY; Zhang XF; Zhang ZW; Fu J; Wen BY; Yu JB; Cao X; Jiang JD
Signal Transduct Target Ther; 2021 Feb; 6(1):77. PubMed ID: 33623004
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
Hansen CA; Miller DR; Annarumma S; Rusch CT; Ramirez-Zamora A; Khoshbouei H
J Neurol; 2022 Jun; 269(6):2892-2909. PubMed ID: 35039902
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China.
Chen W; Xiao Q; Shao M; Feng T; Liu WG; Luo XG; Chen XC; Xie AM; Liu CF; Liu ZG; Liu YM; Wang J; Chen SD
Transl Neurodegener; 2014; 3(1):26. PubMed ID: 25671102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
